

Jill M Kolesar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8044070/publications.pdf>

Version: 2024-02-01

228
papers

5,768
citations

93792

39
h-index

120465

65
g-index

234
all docs

234
docs citations

234
times ranked

9988
citing authors

#	ARTICLE	IF	CITATIONS
1	hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 863.	1.7	4
2	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. <i>Molecular Cancer</i> , 2022, 21, 61.	7.9	6
3	Editorial: Anticancer Potential of <i>Artemisia annua</i> . <i>Frontiers in Oncology</i> , 2022, 12, 853406.	1.3	1
4	Preliminary Research on a COVID-19 Test Strategy to Guide Quarantine Interval in University Students. <i>Covid</i> , 2022, 2, 254-260.	0.7	1
5	Targetable IDH1 mutation identified in a rare case of pancreatic serous cystadenocarcinoma but not a series of serous cystadenomas. <i>Journal of Surgical Case Reports</i> , 2022, 2022, rjac096.	0.2	1
6	Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted Therapy. <i>Diagnostics</i> , 2022, 12, 842.	1.3	15
7	Precision Oncology in Colorectal Cancers- Therapeutics and Beyond (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
8	Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy. <i>Cancers</i> , 2022, 14, 2220.	1.7	30
9	O3 Molecular tumor board assisted care in an advanced cancer population: Results of a phase 2 clinical trial. <i>Gynecologic Oncology</i> , 2022, 165, S2.	0.6	1
10	Macrophage-Engineered Vesicles for Therapeutic Delivery and Bidirectional Reprogramming of Immune Cell Polarization. <i>ACS Omega</i> , 2021, 6, 3847-3857.	1.6	21
11	Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry. <i>Cancer Medicine</i> , 2021, 10, 2054-2062.	1.3	1
12	Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment. <i>Diagnostics</i> , 2021, 11, 395.	1.3	11
13	Precision medicine: Opportunities for health-system pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 999-1003.	0.5	3
14	KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 1885.	1.7	7
15	Gender inequity and sexual harassment in the pharmacy profession: Evidence and call to action. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 2059-2076.	0.5	21
16	Clinical Outcomes of Molecular Tumor Boards: A Systematic Review. <i>JCO Precision Oncology</i> , 2021, 5, 1122-1132.	1.5	43
17	Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance. <i>Biomedicines</i> , 2021, 9, 1021.	1.4	13
18	Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0254205.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Clinical utility of identification and return of research germline mutation results to gynecologic cancer patients enrolled in total cancer care. <i>Gynecologic Oncology</i> , 2021, 162, S112.	0.6	0
20	Prevalence of SARS-CoV-2 IgG antibodies in health care workers at a tertiary care academic medical center – An assessment of occupational infection risk. <i>American Journal of Infection Control</i> , 2021, 49, 1158-1161.	1.1	0
21	Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes. <i>Cancers</i> , 2021, 13, 4524.	1.7	6
22	Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1530-1539.	1.5	10
23	Pediatric patient with peritoneal mesothelioma harboring ALK rearrangement. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100074.	0.1	0
24	Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer. <i>Biomedicines</i> , 2021, 9, 70.	1.4	7
25	MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer. <i>Diagnostics</i> , 2021, 11, 84.	1.3	15
26	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). <i>Clinical Cancer Research</i> , 2021, 27, 1604-1611.	3.2	18
27	Gender inequity and sexual harassment in the pharmacy profession: Evidence and call to action executive summary. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 1375-1378.	0.5	2
28	Liquid biopsy approaches for pleural effusion in lung cancer patients. <i>Molecular Biology Reports</i> , 2020, 47, 8179-8187.	1.0	20
29	Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors. <i>JAMA Network Open</i> , 2020, 3, e2025826.	2.8	24
30	Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy. <i>Cancers</i> , 2020, 12, 2121.	1.7	26
31	Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky. <i>Journal of Rural Health</i> , 2020, .	1.6	3
32	Genomic Analysis of Pancreatic Serous Cystic Neoplasms: Comparison of a Rare Case of Serous Cystadenocarcinoma to a Cohort of Serous Cystadenomas. <i>Journal of the American College of Surgeons</i> , 2020, 231, e158-e159.	0.2	0
33	EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. <i>PLoS ONE</i> , 2020, 15, e0237790.	1.1	10
34	Gynecologic large cell neuroendocrine carcinoma: A review. <i>Rare Tumors</i> , 2020, 12, 203636132096840.	0.3	10
35	CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. <i>Diagnostics</i> , 2020, 10, 279.	1.3	59
36	Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells. <i>Diagnostics</i> , 2020, 10, 121.	1.3	30

#	ARTICLE	IF	CITATIONS
37	Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer. American Journal of Health-System Pharmacy, 2020, 77, 346-351.	0.5	40
38	DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. PLoS ONE, 2020, 15, e0244558.	1.1	10
39	EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. , 2020, 15, e0237790.		0
40	EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. , 2020, 15, e0237790.		0
41	EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. , 2020, 15, e0237790.		0
42	EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. , 2020, 15, e0237790.		0
43	EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. , 2020, 15, e0237790.		0
44	EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky. , 2020, 15, e0237790.		0
45	DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.		0
46	DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.		0
47	DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.		0
48	DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.		0
49	Cell-Derived Vesicles for in Vitro and in Vivo Targeted Therapeutic Delivery. ACS Omega, 2019, 4, 12657-12664.	1.6	16
50	Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. Journal of Clinical Medicine, 2019, 8, 373.	1.0	107
51	Pharmacogenomic potential in advanced cancer patients. American Journal of Health-System Pharmacy, 2019, 76, 415-423.	0.5	7
52	A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. Cancer Prevention Research, 2019, 12, 903-912.	0.7	6
53	Biliary tract large cell neuroendocrine carcinoma: current evidence. Orphanet Journal of Rare Diseases, 2019, 14, 266.	1.2	8
54	Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).. Journal of Clinical Oncology, 2019, 37, 4502-4502.	0.8	36

#	ARTICLE	IF	CITATIONS
55	EML4“ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 965-968.	1.1	7
56	Smoking, Sex, and Non“Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). <i>Journal of the National Cancer Institute</i> , 2018, 110, 734-742.	3.0	32
57	ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 23-54.	0.5	19
58	Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 348-353.	0.5	3
59	Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status. <i>Oncotarget</i> , 2018, 9, 14738-14740.	0.8	24
60	Low-Fat Abiraterone Food Effect Is of Little Consequence. <i>Journal of Clinical Oncology</i> , 2018, 36, 1385-1386.	0.8	15
61	Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 3065-3066.	0.8	1
62	OA06.01 Case-Series Study in Ever- and Never-Smoking Females and Males with NSCLC: Exposures, Tumor Factors, Biology and Survival (SWOG S0424). <i>Journal of Thoracic Oncology</i> , 2018, 13, S333.	0.5	2
63	Defective DNA repair in hereditary ovarian cancers: Implications for therapy. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1697-1707.	0.5	4
64	Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 211-219.	1.1	4
65	Pharmacokinetics in Clinical Oncology. , 2018, , .		0
66	A phase 1/2 trial of ublituximab, a novel anti“CD</sc>20 monoclonal antibody, in patients with B“cell non“Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. <i>British Journal of Haematology</i> , 2017, 177, 243-253.	1.2	61
67	Dinutuximab for maintenance therapy in pediatric neuroblastoma. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 563-567.	0.5	22
68	New options and controversies in the management of chemotherapy-induced nausea and vomiting. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 812-819.	0.5	9
69	A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers. <i>Cancer Prevention Research</i> , 2017, 10, 298-307.	0.7	54
70	A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 290-297.	1.2	20
71	A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26409.	0.8	66
72	Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. <i>Investigational New Drugs</i> , 2017, 35, 87-94.	1.2	9

#	ARTICLE	IF	CITATIONS
73	Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	1.5	18
74	A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. <i>PLoS ONE</i> , 2017, 12, e0178593.	1.1	38
75	Abstract P4-22-21: NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors. , 2017, , .		0
76	Pharmacodynamic phase I study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14088-e14088.	0.8	0
77	EPT-08A PHASE I STUDY OF SINGLE-AGENT PERIFOSINE FOR RECURRENT/REFRACTORY PEDIATRIC CNS AND SOLID TUMORS. <i>Neuro-Oncology</i> , 2016, 18, iii25.3-iii25.	0.6	0
78	Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. <i>European Journal of Cancer Prevention</i> , 2016, 25, 312-320.	0.6	10
79	Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2659-2667.	3.2	39
80	MP04-14 PHASE IIA, RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SINGLE HIGH DOSE CHOLECALCIFEROL (VITAMIN D 3) AND DAILY GENISTEIN (G-2535) VERSUS PLACEBO IN MEN WITH EARLY STAGE PROSTATE CANCER UNDERGOING PROSTATECTOMY. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
81	Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1037-1041.	0.5	21
82	Precision medicine in oncology: New practice models and roles for oncology pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1935-1942.	0.5	34
83	18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1245-1252.	1.1	4
84	Prioritization of family member sequencing for the detection of rare variants. <i>BMC Proceedings</i> , 2016, 10, 227-231.	1.8	1
85	A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. <i>Investigational New Drugs</i> , 2016, 34, 225-230.	1.2	9
86	Assessment of adherence with oral anticancer agents in oncology clinical trials: A systematic review. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 105-113.	0.5	8
87	Treatment of chronic myelogenous leukemia. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 113-120.	0.5	14
88	Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 193-201.	0.5	75
89	A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. <i>Investigational New Drugs</i> , 2016, 34, 168-175.	1.2	40
90	Abstract OT3-02-06: A phase 1 study of BMN 673 in combination with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782). , 2016, , .		0

#	ARTICLE	IF	CITATIONS
91	Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. American Journal of Clinical and Experimental Urology, 2016, 4, 17-27.	0.4	5
92	MP26-01 A PHASE II RANDOMIZED, PRESURGICAL PLACEBO-CONTROLLED TRIAL OF POLYPHENON E IN BLADDER CANCER PATIENTS TO EVALUATE BLADDER TISSUE LEVELS OF EGCG AND BIOMARKERS OF GROWTH AND APOPTOSIS. Journal of Urology, 2015, 193, .	0.2	0
93	Threeâ€arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced nonâ€small cell lung cancer (NSCLC) patients who will not receive bevacizumabâ€based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer, 2015, 121, 2253-2261.	2.0	21
94	Pharmacokinetic/Toxicity Properties of the New Anti-Staphylococcal Lead Compound SK-03-92. Antibiotics, 2015, 4, 617-626.	1.5	2
95	Potential cytochrome P-450 drugâ€drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. American Journal of Health-System Pharmacy, 2015, 72, 958-965.	0.5	11
96	Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. American Journal of Health-System Pharmacy, 2015, 72, 1456-1462.	0.5	20
97	Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. Journal of Oncology Pharmacy Practice, 2015, 21, 128-131.	0.5	1
98	A multicenter phase 1 study of Î³-secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational New Drugs, 2015, 33, 169-176.	1.2	32
99	Opportunities for drug repositioning from phenome-wide association studies. Nature Biotechnology, 2015, 33, 342-345.	9.4	109
100	Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer. American Journal of Health-System Pharmacy, 2015, 72, 1851-1855.	0.5	21
101	Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3â€deoxy-3â€fluoro-l-thymidine positron emission tomography/computed tomography. Cancer Chemotherapy and Pharmacology, 2015, 76, 187-195.	1.1	11
102	Importance of ethnicity and smoking status in EGFR gene testing in lung cancers. American Journal of Health-System Pharmacy, 2015, 72, 686-687.	0.5	0
103	A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1Î±,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. Journal of Oncology Pharmacy Practice, 2015, 21, 416-424.	0.5	0
104	Phase 1/2a, open-label, dose-escalation and safety study of APC-100 in men with advanced prostate cancer.. Journal of Clinical Oncology, 2015, 33, 234-234.	0.8	0
105	Abstract P5-19-20: A phase I study of MK-2206 in combination with lapatinib in patients with advanced solid tumors followed by dose-expansion in advanced HER2+ breast cancer. , 2015, , .		0
106	A phase I study of ARQ 197 in combination with temsirolimus in advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 2554-2554.	0.8	0
107	Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.. Journal of Clinical Oncology, 2015, 33, TPS2601-TPS2601.	0.8	0
108	Abstract A20: A phase II randomized, presurgical placebo-controlled trial of polyphenon E in bladder cancer patients to evaluate bladder tissue levels of EGCG and biomarkers of growth and apoptosis. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
109	Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 793-798.	0.5	12
110	Serotonin type 3 receptor antagonists for chemotherapy-induced nausea and vomiting: Therapeutically equivalent or meaningfully different?. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 507-510.	0.5	11
111	Clinical Pharmacogenetics. <i>Cancer Drug Discovery and Development</i> , 2014, , 803-821.	0.2	0
112	A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. <i>Investigational New Drugs</i> , 2014, 32, 295-302.	1.2	36
113	A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 485-493.	1.1	14
114	Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. <i>Investigational New Drugs</i> , 2014, 32, 195-199.	1.2	35
115	Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 1933-1938.	0.5	16
116	Prevention and treatment of chemotherapy-induced peripheral neuropathy. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 19-25.	0.5	76
117	A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 323-329.	1.2	36
118	Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). <i>European Journal of Cancer</i> , 2014, 50, 302-308.	1.3	23
119	Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 538-538.	0.8	2
120	Cytochrome P450 interacting medication use in adult advanced solid tumor and phase I trial patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2591-2591.	0.8	0
121	A phase I study of ARQ 197 in combination with temsirolimus in patients (Pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2555-2555.	0.8	0
122	A phase II study of sorafenib (BAY 439006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). <i>Journal of Hematology and Oncology</i> , 2013, 6, 46.	6.9	10
123	New treatment options for castration-resistant prostate cancer. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 856-865.	0.5	6
124	Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 661-667.	1.1	3
125	A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. <i>Investigational New Drugs</i> , 2013, 31, 1539-1546.	1.2	26
126	Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 211-218.	0.8	22

#	ARTICLE	IF	CITATIONS
127	Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1405-1414.	0.8	188
128	Crizotinib for the treatment of non-small-cell lung cancer. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 943-947.	0.5	23
129	Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 849-855.	0.5	24
130	A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. <i>Annals of Oncology</i> , 2013, 24, 3076-3081.	0.6	45
131	Stability of stock and diluted rituximab. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 436-438.	0.5	15
132	Assays for biological agents. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1101-1101.	0.5	2
133	Vemurafenib and ipilimumab: New agents for metastatic melanoma. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1205-1210.	0.5	16
134	Unexpected doxorubicin-mediated cardiotoxicity in sisters: Possible role of polymorphisms in histamine n-methyl transferase. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 269-272.	0.5	10
135	Vismodegib for the treatment of basal cell skin cancer. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1033-1038.	0.5	17
136	Phase II open label, multicenter clinical trial of modulation of intermediate endpoint biomarkers by 1 α -hydroxyvitamin D ₂ in patients with clinically localized prostate cancer and high grade pin. <i>Prostate</i> , 2013, 73, 970-978.	1.2	32
137	A pharmacodynamic trial of sequential sunitinib (Su) with bevacizumab (Bev) in patients (Pts) with renal cell carcinoma and other advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 434-434.	0.8	0
138	Stability of infliximab in polyvinyl chloride bags. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1509-1512.	0.5	17
139	EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 245-249.	0.5	6
140	Lenalidomide-induced elevated bilirubin. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 402-405.	0.5	7
141	Exemestane for primary prevention of breast cancer in postmenopausal women. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1384-1388.	0.5	13
142	A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients. <i>Cancer Prevention Research</i> , 2012, 5, 621-630.	0.7	76
143	Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 623-633.	1.5	90
144	Targeted therapy for NSCLC: ALK inhibition. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 271-274.	0.5	7

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin. <i>Journal of Controlled Release</i> , 2012, 163, 93-99.	4.8	46
146	Unexpected doxorubicin-induced cardiomyopathy in sisters. <i>International Cancer Conference Journal</i> , 2012, 1, 15-18.	0.2	2
147	A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels. <i>Blood</i> , 2012, 120, 1640-1640.	0.6	1
148	Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma. <i>Blood</i> , 2012, 120, 5041-5041.	0.6	3
149	A 3-in-1 Polymeric Micelle Nanocontainer for Poorly Water-Soluble Drugs. <i>Molecular Pharmaceutics</i> , 2011, 8, 1257-1265.	2.3	109
150	Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells. <i>Oncology Letters</i> , 2011, 2, 91-94.	0.8	11
151	The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. <i>Oncology Reports</i> , 2011, 25, 1765-72.	1.2	21
152	Temozolomide-induced severe myelosuppression. <i>Anti-Cancer Drugs</i> , 2011, 22, 104-110.	0.7	19
153	Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells. <i>International Journal of Oncology</i> , 2011, 38, 513-9.	1.4	13
154	Cytotoxic evaluation of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in peripheral blood lymphocytes of patients with refractory solid tumors using electron paramagnetic resonance. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 119-123.	0.8	6
155	Eltrombopag: An Oral Thrombopoietin Receptor Agonist for the Treatment of Idiopathic Thrombocytopenic Purpura. <i>Clinical Therapeutics</i> , 2011, 33, 1560-1576.	1.1	23
156	Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 393-400.	1.1	40
157	Cetuximab for the Treatment of Advanced Bronchioloalveolar Carcinoma (BAC): An Eastern Cooperative Oncology Group Phase II Study (ECOG 1504). <i>Journal of Clinical Oncology</i> , 2011, 29, 1709-1714.	0.8	20
158	Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate. <i>Clinical Cancer Research</i> , 2011, 17, 7634-7644.	3.2	62
159	Stability of unused reconstituted bortezomib in original manufacturer vials. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 400-402.	0.5	22
160	Abstract 4396: Evaluation of gene expression and transcriptional activation in patients treated with vorinostat. , 2011, , .		0
161	Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 853-857.	0.8	10
162	Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells. <i>Molecular Medicine Reports</i> , 2010, 3, 1031-4.	1.1	12

#	ARTICLE	IF	CITATIONS
163	A Bayesian adaptive design with biomarkers for targeted therapies. <i>Clinical Trials</i> , 2010, 7, 546-556.	0.7	25
164	The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 973-980.	1.1	16
165	A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. <i>Investigational New Drugs</i> , 2010, 28, 91-97.	1.2	97
166	A Pilot, First-in-Human, Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. <i>Cancer Prevention Research</i> , 2010, 3, 1565-1570.	0.7	32
167	The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes. <i>Journal of Oncology Pharmacy Practice</i> , 2010, 16, 223-232.	0.5	13
168	Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ3 Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy. <i>Cancer Research</i> , 2010, 70, 9554-9561.	0.4	163
169	Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3491-3497.	0.8	246
170	Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 223-226.	0.5	21
171	Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 793-797.	0.5	86
172	Clinical significance of ABCB1 genotyping in oncology. <i>Journal of Oncology Pharmacy Practice</i> , 2010, 16, 39-44.	0.5	50
173	Clinical and economic value of screening for <i>Kras</i> mutations as predictors of response to epidermal growth factor receptor inhibitors. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 2105-2112.	0.5	24
174	Stability of Alemtuzumab for Low-Dose Induction and Test Doses. <i>American Journal of Transplantation</i> , 2009, 9, 651-652.	2.6	7
175	Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. <i>Clinical Therapeutics</i> , 2009, 31, 2332-2348.	1.1	97
176	Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma. <i>Clinical Therapeutics</i> , 2009, 31, 2290-2311.	1.1	37
177	Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. <i>Hematological Oncology</i> , 2009, 27, 11-16.	0.8	35
178	Docetaxel and irinotecan in recurrent or metastatic head and neck cancer. <i>Cancer</i> , 2009, 115, 4504-4513.	2.0	24
179	A phase I study of an oral simulated FOLFOX with high dose capecitabine. <i>Investigational New Drugs</i> , 2009, 27, 461-468.	1.2	7
180	Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1073-1082.	1.1	7

#	ARTICLE	IF	CITATIONS
181	Evaluation of mRNA by Q-RT-PCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 79-86.	1.1	15
182	A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1147-1156.	1.1	31
183	Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 64, 51-59.	0.9	82
184	Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study. <i>Journal of Thoracic Oncology</i> , 2009, 4, 522-526.	0.5	133
185	The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).. <i>Blood</i> , 2009, 114, 3885-3885.	0.6	7
186	A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. <i>Investigational New Drugs</i> , 2008, 26, 369-379.	1.2	74
187	A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 109-115.	1.1	17
188	Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine®. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 693-698.	1.5	28
189	Gene-expression assays: New tools to individualize treatment of early-stage breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 23-28.	0.5	33
190	Hydroxyurea induced acute elevations in liver function tests. <i>Journal of Oncology Pharmacy Practice</i> , 2008, 14, 61-63.	0.5	4
191	A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 2732-2739.	3.2	17
192	Chemoprevention of breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 2221-2228.	0.5	31
193	Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 123-131.	0.5	54
194	Bortezomib: A novel chemotherapeutic agent for hematologic malignancies. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 1221-1231.	0.5	48
195	Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). <i>Annals of Oncology</i> , 2008, 19, 1417-1422.	0.6	16
196	Stability of a heparin-free 50% ethanol lock solution for central venous catheters. <i>Journal of Oncology Pharmacy Practice</i> , 2007, 13, 33-37.	0.5	7
197	EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 406-412.	0.5	20
198	Pharmacogenetics and irinotecan therapy. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2211-2217.	0.5	45

#	ARTICLE	IF	CITATIONS
199	The State of Science and Research in Clinical Pharmacy. <i>Pharmacotherapy</i> , 2006, 26, 1027-1040.	1.2	78
200	Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2340-2348.	0.5	58
201	Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 527-533.	0.5	8
202	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. <i>Journal of Thoracic Oncology</i> , 2006, 1, 52-60.	0.5	13
203	Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. <i>Journal of Thoracic Oncology</i> , 2006, 1, 52-60.	0.5	10
204	EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 406-12.	0.5	12
205	Bevacizumab: Improved survival at what cost?. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1017-1017.	0.5	6
206	Azacitidine: A novel agent for myelodysplastic syndromes. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1567-1573.	0.5	18
207	Phase I Trial of a Monoclonal Antibody Specific for $\alpha_3\beta_1$ Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion. <i>Clinical Cancer Research</i> , 2005, 11, 7851-7860.	3.2	147
208	A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 6625-6633.	3.2	158
209	Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 1365-1369.	0.5	1
210	Palifermin (Kepivance [®]) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. <i>Journal of Oncology Pharmacy Practice</i> , 2005, 11, 121-125.	0.5	35
211	Clinical pharmacology and determinates of response to gefitinib in non-small cell lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2004, 10, 169-175.	0.5	0
212	A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 7450-7456.	3.2	162
213	Retrospective evaluation of response to epoetin alfa in patients with hematologic disorders. <i>Journal of Oncology Pharmacy Practice</i> , 2004, 10, 1-6.	0.5	2
214	Phase II Trial of Perillyl Alcohol in Patients with Metastatic Colorectal Cancer. <i>International Journal of Gastrointestinal Cancer</i> , 2003, 32, 125-128.	0.4	56
215	Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. <i>International Journal of Oncology</i> , 2002, 21, 1119.	1.4	16
216	Novel approaches to anemia associated with cancer and chemotherapy. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, S8-S11.	0.5	6

#	ARTICLE	IF	CITATIONS
217	NAD(P)H: quinone oxidoreductase enhances proliferation inhibition by 4-hydroxytamoxifen. <i>Anticancer Research</i> , 2002, 22, 1475-80.	0.5	4
218	Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. <i>International Journal of Oncology</i> , 2002, 21, 1119-24.	1.4	14
219	Transmissibility of adenovirus-induced adiposity in a chicken model. <i>International Journal of Obesity</i> , 2001, 25, 990-996.	1.6	109
220	Quantitation of Viral Load. , 2001, , 237-260.		0
221	Direct quantification of AD-36 adenovirus DNA by capillary electrophoresis with laser-induced fluorescence. <i>Biomedical Applications</i> , 2000, 744, 1-8.	1.7	16
222	Increased adiposity in animals due to a human virus. <i>International Journal of Obesity</i> , 2000, 24, 989-996.	1.6	196
223	Identification of a Gemcitabine-Warfarin Interaction. <i>Pharmacotherapy</i> , 1999, 19, 1331-1333.	1.2	17
224	Warfarinâ€™5-FU Interaction â€™ A Consecutive Case Series. <i>Pharmacotherapy</i> , 1999, 19, 1445-1449.	1.2	54
225	Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine. <i>Journal of Oncology Pharmacy Practice</i> , 1997, 3, 94-109.	0.5	0
226	Direct quantification of HIV-1 RNA by capillary electrophoresis with laser-induced fluorescence. <i>Biomedical Applications</i> , 1997, 697, 189-194.	1.7	26
227	Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine. <i>Journal of Oncology Pharmacy Practice</i> , 1996, 2, 160-181.	0.5	2
228	Purine nucleoside analogues: fludarabine, pentostatin, and cladribine. <i>Journal of Oncology Pharmacy Practice</i> , 1996, 2, 211-224.	0.5	2